Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192 |
Tel: | N/A |
Website: | https://www.pfizer.com |
IR: | See website |
Key People | ||
Albert Bourla Chairman of the Board, Chief Executive Officer | Michael Mcdermott Executive Vice President, Chief Global Supply Officer | David M. Denton Executive Vice President, Chief Financial Officer |
Payal Sahni Executive Vice President, Chief People Experience Officer | Lidia L. Fonseca Executive Vice President, Chief Digital and Technology Officer | Rady A. Johnson Executive Vice President, Chief Compliance, Quality and Risk Officer |
Douglas M. Lankler Executive Vice President, General Counsel | Chris Boshoff Executive Vice President, Chief Oncology Officer | Alexandre De Germay Executive Vice President, Chief International Commercial Officer | Aamir Malik Executive Vice President, Chief US Commercial Officer |
Business Overview |
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga. |
Financial Overview |
For the fiscal year ended 31 December 2023, Pfizer Inc revenues decreased 42% to $58.5B. Net income before extraordinary items decreased 93% to $2.13B. Revenues reflect United States segment decrease of 36% to $27.09B, Developed Europe segment decrease of 47% to $11.65B. Net income also reflects Certain asset impairments increase from $421M to $3.02B (expense), Amortization of intangible assets increase of 31% to $4.73B (expense). |